NSW Annual Report Describing Adverse Events Following Immunisation, 2010
Deepika Mahajan A D , Sue Campbell-Lloyd B , Jane Cook C and Robert I. Menzies A
+ Author Affiliations
- Author Affiliations
A National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead
B AIDS and Infectious Diseases Branch, NSW Department of Health
C Office of Medicine Safety Monitoring, Therapeutic Goods Administration
D Corresponding author. Email: DeepikM2@chw.edu.au
NSW Public Health Bulletin 22(10) 196-208 https://doi.org/10.1071/NB11024
Published: 8 November 2011
Abstract
Aim: This report summarises Australian passive surveillance data for adverse events following immunisation in NSW for 2010. Methods: Analysis of de-identified information on all adverse events following immunisation reported to the Therapeutic Goods Administration. Results: 424 adverse events following immunisation were reported for vaccines administered in 2010; this is 6% lower than 2009 but 24% higher than 2008 and the second highest number since 2003. A total of 274 (65%) adverse events involved seasonal or pandemic influenza vaccines. Reports were predominantly of mild transient events: the most commonly reported reactions were fever, allergic reaction, injection site reaction, malaise and headache. Only 9% of the reported adverse events were serious in nature, including eight reports of febrile convulsions in children following seasonal influenza vaccine. Conclusion: The large number of reports in 2010 is attributable to the high rates of fever and febrile convulsions in children after vaccination with 2010 seasonal trivalent influenza vaccine, as well as pandemic (H1N1) 2009 influenza vaccine.
References
[1] Lawrence G, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Commun Dis Intell 2004; 28 324–38.[2] Lawrence G, Boyd I. Surveillance of adverse events following immunisation for children aged less than 7 years, 1 January to 30 June 2004. Commun Dis Intell 2004; 28 490–2.
[3] Lawrence G, Boyd I. Supplementary report: surveillance of adverse events following immunisation among children aged less than 7 years in Australia, 1 January to 30 June 2005. Commun Dis Intell 2005; 29 413–6.
[4] Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2005. Commun Dis Intell 2006; 30 319–33.
[5] Lawrence G, Boyd I. Supplementary report: surveillance of adverse events following immunisation among children aged <7 years in Australia, 1 January to 30 June 2006. Commun Dis Intell 2006; 30 438–42.
[6] Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 2008; 32 371–87.
[7] Lawrence GL, Boyd I, McIntyre PB, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004. Commun Dis Intell 2005; 29 248–62.
[8] Lawrence GL, Aratchige PE, Boyd I, McIntyre PB, Gold MS. Annual report on surveillance of adverse events following immunisation in Australia, 2006. Commun Dis Intell 2007; 31 269–82.
[9] Lawrence GL, Aratchige PE, Hill R. Supplementary report: surveillance of adverse events following immunisation among children aged less than 7 years in Australia, 1 January to 30 June 2007. Commun Dis Intell 2007; 31 379–82.
[10] Lawrence GL, Mahajan D, Roomiani I. Supplementary report: surveillance of adverse events following immunisation among children aged <7 years in Australia, 1 January to 30 June 2008. Commun Dis Intell 2009; 33 27–31.
[11] Mahajan D, Menzies R, Roomiani I, Lawrence GL. Supplementary report: surveillance of adverse events following immunisation among children aged <7 years in Australia, 1 January to 30 June 2009. Commun Dis Intell 2010; 34 49–53.
[12] Menzies R, Mahajan D, Gold MS, Roomiani I, McIntyre P, Lawrence G. Annual report: surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intell 2009; 33 365–81.
[13] Victorian State Government, Department of Health. National immunisation program schedule. Available from: http://health.vic.gov.au/immunisation/fact-sheets/factsheets/schedule_victoria (Cited 1 December 2010.)
[14] Australian Government Department of Health and Ageing, Therapeutic Goods Administration. TGA approves vaccine against pandemic (H1N1) 2009 influenza. 18 September 2009. Available from: http://www.tga.gov.au/media/mr2009.htm (Cited 2 December 2010.)
[15] National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. Canberra: Australian Government Department of Health and Ageing; 2003.
[16] National Health and Medical Research Council. The Australian Immunisation Handbook. 9th ed. Canberra: Australian Government Department of Health and Ageing; 2008.
[17] Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. 2009. Available from: http://www.who-umc.org/ (Cited 1 February 2009.)
[18] Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)–United States, 1991–2001. MMWR Surveill Summ 2003; 52 1–24.
[19] Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20 109–17.
| The medical dictionary for regulatory activities (MedDRA).Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3cXltleksQ%3D%3D&md5=eacb06d5f70a44b476f08228f29111b9CAS |
[20] Bonhoeffer J, Gold MS, Heijbel H, Vermeer P, Blumberg D, Braun M, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004; 22 563–8.
| Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.Crossref | GoogleScholarGoogle Scholar |
[21] Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25 5675–84.
| Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.Crossref | GoogleScholarGoogle Scholar |
[22] Australian Bureau of Statistics. 31010DO002_201006 Population by Age and Sex, Australian States and Territories, Jun 2010. Australian Bureau of Statistics; 2010. Released at 11:30 am (Canberra time) 21 December 2010.
[23] Centre for Epidemiology and Research. Summary report on adult health from the NSW Population Health Survey, 2009. Sydney: NSW Department of Health; 2010.
[24] Mahajan D, Campbell-Lloyd S, Roomiani I, Menzies R. NSW Annual Adverse Events Following Immunisation Report, 2009. N S W Public Health Bull 2010; 21 224–33.
| NSW Annual Adverse Events Following Immunisation Report, 2009.Crossref | GoogleScholarGoogle Scholar |
[25] World Health Organization Safety of pandemic A (H1N1) influenza vaccines. Wkly Epidemiol Rec 2010; 85 29–36.
[26] Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303 37–46.
| Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: a randomized trial.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXjtFKrtA%3D%3D&md5=f624147b4822059971b5426a2679c72cCAS |
[27] Australian Government Department of Health and Ageing. Therapeutic Goods Administration, Cook J. Australian experience with non-adjuvant H1N1 vaccine (Panvax and Panvax Junior). Medicines Safety Update No. 4, 2010. Available from: http://www.tga.gov.au/adr/msu/msu1008.htm#austexper (Cited 30 August 2010.)
[28] Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Australian Technical Advisory Group on Immunisation (ATAGI) and Therapeutic Goods Administration (TGA) Joint Working Group. Analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine (Panvax/Panvax Junior, CSL). Available from: http://www.tga.gov.au/safety/alerts-medicine-seasonal-flu-100928.htm (Cited 30 May 2011.)
[29] Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Suspected adverse reactions to Panvax® reported to the TGA. 30 September 2009 to 17 September 2010. Available from: http://www.tga.gov.au/safety/alerts-medicine-panvax-091120.htm (Cited 30 May 2011.)
[30] Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination. Status report as at 2 July 2010 (updated 24 September 2010). Available from: http://www.tga.gov.au/safety/alerts-medicine-seasonal-flu-100702.htm (Cited 30 May 2011.)
[31] Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Departmental Media Releases 23 April 2010. Seasonal Flu Vaccine and young children. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/mr-yr10-dept-dept230410.htm (Cited 30 May 2011.)
[32] Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Departmental Media Releases 30 July 2010. Seasonal flu vaccination for young children can be resumed – Updated advice from the Chief Medical Officer. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/mr-yr10-dept-dept300710.htm (Cited 30 May 2011.)
